MTOR and lymphangioleiomyomatosis: Current evidence indicates that lymphangioleiomyomatosis (LAM) arises from TSC1/2 gene mutations driving constitutive activation of the mTOR signaling pathway, which promotes dysregulated proliferation of neoplastic LAM cells.